Easier Injections for Multiple Myeloma Cancer Treatment
This patent describes specific liquid mixtures (formulations) of anti-CD38 antibodies designed to be injected just under the skin for treating multiple myeloma, making administration simpler than traditional intravenous methods.
Original patent title: “Subcutaneous formulations of daratumumab and their uses in treating multiple myeloma”
This patent describes specific liquid mixtures (formulations) of anti-CD38 antibodies designed to be injected just under the skin for treating multiple myeloma, making administration simpler than traditional intravenous methods. Granted in 2026.
Coverage
What does this patent actually cover?
This patent describes specific ways to create a liquid medicine (a 'formulation') containing anti-CD38 antibodies so it can be injected just under the skin ('subcutaneously'). The goal is to make it easier to give this medicine, which is used to treat a type of blood cancer called multiple myeloma. While the specific claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more → are not available, the invention focuses on the precise mix of ingredients that allows the anti-CD38 antibody to be delivered effectively and safely via a subcutaneous shot, rather than through a vein. For example, instead of a long infusion at a clinic, a patient could receive a quicker injection.
The gap
What does this patent NOT cover?
- Does not cover intravenous (IV) formulations of anti-CD38 antibodies, only those designed for subcutaneous injection.
- Does not cover formulations of other types of antibodies or drugs that are not anti-CD38 antibodies.
- Does not cover treatments for cancers other than multiple myeloma, as specified in the abstractabstractA short summary at the front of the patent describing the invention. Not legally binding.Read more →.
- Does not cover the anti-CD38 antibody molecule itself, only its specific preparation for subcutaneous use.
- Does not cover methods of treatment that do not involve administering the specific subcutaneous formulation.
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
Key facts
What made this novel
The clever bit is figuring out how to make a large, complex protein like an anti-CD38 antibody stable and effective when injected in a small volume under the skin. This is challenging because such proteins often need to be highly concentrated and can be unstable or painful when administered subcutaneously, requiring specific stabilizing ingredients and precise pH levels.
Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
Darzalex Faspro (daratumumab and hyaluronidase-fihj)
Other subcutaneous biologic drug formulations for chronic conditions
Oncology treatment centers using subcutaneous injections
Why it matters
The bigger picture
This patent aims to improve how a vital cancer drug is given to patients. Subcutaneous injections are generally quicker, less invasive, and more convenient than intravenous infusions, which often require longer visits to a clinic. This can significantly improve the patient experience and reduce the burden on healthcare facilities, making life easier for those undergoing treatment for multiple myeloma.
Filed
January 14, 2026
Granted
September 15, 2026
Market context
Who's building on this
Companies in this space
Janssen Biotech, a pharmaceutical company under Johnson & Johnson, is the original developer of daratumumab (Darzalex) and has successfully brought a subcutaneous formulation (Darzalex Faspro) to market. Other pharmaceutical companies are also actively researching and developing subcutaneous formulations for various biologic drugs to enhance patient convenience and reduce healthcare costs.
Market impact
The development of subcutaneous formulations for drugs like daratumumab has significantly shifted the treatment paradigm for multiple myeloma. It has allowed for more flexible administration, moving some treatments from hospital-based intravenous infusions to quicker, potentially clinic or home-based subcutaneous injections. This change improves patient quality of life and reduces the operational burden on infusion centers, impacting healthcare resource allocation and patient access to care.
Claim 1 — Plain English
What this patent covers
This patent describes specific ways to create a liquid medicine (a 'formulation') containing anti-CD38 antibodies so it can be injected just under the skin ('subcutaneously'). The goal is to make it easier to give this medicine, which is used to treat a type of blood cancer called multiple myeloma. While the specific claims are not available, the invention focuses on the precise mix of ingredients that allows the anti-CD38 antibody to be delivered effectively and safely via a subcutaneous shot, rather than through a vein. For example, instead of a long infusion at a clinic, a patient could receive a quicker injection.
The clever bit
The clever bit is figuring out how to make a large, complex protein like an anti-CD38 antibody stable and effective when injected in a small volume under the skin. This is challenging because such proteins often need to be highly concentrated and can be unstable or painful when administered subcutaneously, requiring specific stabilizing ingredients and precise pH levels.
What it does not cover
- Does not cover intravenous (IV) formulations of anti-CD38 antibodies, only those designed for subcutaneous injection.
- Does not cover formulations of other types of antibodies or drugs that are not anti-CD38 antibodies.
- Does not cover treatments for cancers other than multiple myeloma, as specified in the abstract.
- Does not cover the anti-CD38 antibody molecule itself, only its specific preparation for subcutaneous use.
- Does not cover methods of treatment that do not involve administering the specific subcutaneous formulation.
Patent timeline
Application submitted to the patent office
Patent officially issued
PatentBrief Score
Impact Score
Early stage
Citation count
0/40
No citations yet
Claim breadth
0/20
Narrow claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →
Recency
20/20
Granted within 5 years
Assignee scale
0/20
Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$36K – $115K
Midpoint $72K · 19.3 yr remaining · industry ×3.0
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
Claim text not yet imported for this patent
Concepts involved
Cite this patent
(2026). Easier Injections for Multiple Myeloma Cancer Treatment (U.S. Patent No. 12,735,501). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/12735501/subcutaneous-formulations-of-daratumumab-and-their-uses-in-treating-multiple
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="US12735501"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does Easier Injections for Multiple Myeloma Cancer Treatment cover?
This patent describes specific liquid mixtures (formulations) of anti-CD38 antibodies designed to be injected just under the skin for treating multiple myeloma, making administration simpler than traditional intravenous methods.
When does this patent expire?
This patent is expected to expire on September 15, 2046, when the invention enters the public domain.
What problem does this patent solve?
This patent aims to improve how a vital cancer drug is given to patients. Subcutaneous injections are generally quicker, less invasive, and more convenient than intravenous infusions, which often require longer visits to a clinic. This can significantly improve the patient experience and reduce the burden on healthcare facilities, making life easier for those undergoing treatment for multiple myeloma.
What does this patent NOT cover?
Does not cover intravenous (IV) formulations of anti-CD38 antibodies, only those designed for subcutaneous injection.
Patent monitoring